1-3 of 3
B. Lowenberg, MD
Close
Sort by
Journal Articles

A Multicentre Phase II Study of the Aminopeptidase Inhibitor, CHR- 2797, in the Treatment of Elderly and/or Previously Treated patients with Acute Myeloid Leukemia.

B. Lowenberg, MD, F. Davies, MD, C. Müller-Tidow, MD, Ulrich Dührsen, A. Burnett, MD, FRCP, P. Zachée, MD, PhD, D. Dierickx, MD, C. Jenkins, MD, P. Sonneveld, MD, M. Jongen-Lavrencic, MD, S. Zweegman, MD, G. Morgan, MD, U. Krug, MD, A. Richardson, PhD, L. Hooftman, MD, G. Ossenkoppele, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 961.
https://doi.org/10.1182/blood.V112.11.961.961
Published: 2008
Journal Articles

Mutant Wilms’ Tumor 1 ( WT1 ) mRNA with Premature Termination Codons Is Sensitive to Nonsense-Mediated RNA Decay in Acute Myeloid Leukemia (AML)

Saman Abbas, Claudia Erpelinck, Chantal Goudswaard, B. Lowenberg, MD, Peter Valk, PhD
Journal: Blood
Blood (2008) 112 (11): 2538.
https://doi.org/10.1182/blood.V112.11.2538.2538
Published: 2008
Journal Articles

Gene Expression Profiles with Signatures of Tumor Biology and Chemotherapy Sensitivity May Provide a Novel Approach to Maximize Response to Induction Therapy in Patients with Acute Myeloid Leukemia.

Arati V Rao, Sascha A Tuchman, Anil Potti, David A. Rizzieri, MD, Hiroyuki Mano, Ruud Delwel, PhD, Peter Valk, B. Lowenberg, MD
Journal: Blood
Blood (2008) 112 (11): 2252.
https://doi.org/10.1182/blood.V112.11.2252.2252
Published: 2008